VOMITHIXA

10X15 TABLETS

VOMITHIXA contains Ondansetron, a selective 5-HT3 receptor antagonist used to prevent and treat nausea and vomiting caused by chemotherapy, radiation therapy, or surgery. It works by blocking serotonin, a natural substance in the body that can trigger nausea and vomiting. These orally disintegrating tablets dissolve quickly in the mouth without the need for water, making them convenient for patients experiencing nausea.

While VOMITHIXA is generally well tolerated, some patients may experience the following side effects:

• Headache
• Dizziness
• Fatigue
• Constipation or Diarrhea
• Dry mouth
• Flushing
• Rarely, allergic reactions (rash, itching, swelling)
• QT prolongation (irregular heart rhythm in rare cases)

If any severe side effects occur, such as chest pain, fainting, or severe dizziness, seek immediate medical attention.

• Place the orally disintegrating tablet on the tongue; it dissolves quickly and can be swallowed without water.
• Take as prescribed by your doctor before chemotherapy, radiation therapy, or surgery.
• If using it for motion sickness or other nausea causes, follow the exact dosage instructions from your healthcare provider.

• Effectiveness: Works best when taken before nausea starts rather than after vomiting begins.
• Pregnancy & Breastfeeding: Generally safe in pregnancy (Category B), but consult a doctor before use. Limited data on breastfeeding safety.
• Elderly Patients: May require dosage adjustments due to metabolism differences.
• Liver Disease: Use with caution as Ondansetron is metabolized in the liver.

• Patients with known allergy to Ondansetron or any other 5-HT3 receptor antagonist.
• People with congenital long QT syndrome, as it can worsen heart rhythm problems.
• Patients taking Apomorphine due to the risk of severe hypotension and loss of consciousness.

• QT Prolongation Risk: Can cause abnormal heart rhythms, especially in people with heart disease.
• Serotonin Syndrome: May occur if used with SSRIs or SNRIs (antidepressants). Symptoms include confusion, fever, and muscle twitching.
• Electrolyte Imbalance: Patients with low potassium or magnesium levels should use with caution.
• Liver Impairment: Dose adjustments may be required in severe liver disease.

For Chemotherapy-Induced Nausea and Vomiting (CINV):

• Adults & Adolescents (≥12 years): 8 mg 30 minutes before chemotherapy, followed by 8 mg after 8 hours, then 8 mg every 12 hours for 1-2 days post-treatment.
• Children (4-11 years): 4 mg 30 minutes before chemotherapy, followed by 4 mg after 4 and 8 hours, then 4 mg every 8 hours for 1-2 days.

For Postoperative Nausea and Vomiting (PONV):

• Adults: 16 mg one hour before anesthesia or 4 mg as a single dose.
• Children: Not typically recommended for surgical nausea prevention.

For Radiation Therapy-Induced Nausea:

• Adults: 8 mg 1-2 hours before radiation therapy, followed by 8 mg every 8-12 hours during treatment.

Missed Dose:

• Take the missed dose as soon as possible. If it's close to the next dose, skip it—do not double the dose.

• Apomorphine: Risk of severe hypotension and unconsciousness.
• Antidepressants (SSRIs, SNRIs, MAOIs): May increase the risk of serotonin syndrome.
• Antiarrhythmics & Beta-blockers: May enhance QT prolongation risk.
• Rifampin, Carbamazepine, Phenytoin: Can reduce Ondansetron effectiveness.
• Tramadol: May reduce pain relief effectiveness.

• Take exactly as prescribed; do not self-medicate or alter doses.
• Do not chew, break, or crush the orally disintegrating tablet.
• Avoid alcohol while using VOMITHIXA.
• Store in a cool, dry place, away from moisture and direct sunlight.
• Inform your doctor about all medications and supplements you are taking.

• Brand Name: VOMITHIXA
• Composition: Ondansetron Orally Disintegrating Tablets IP
• Form: Orally disintegrating tablet
• Storage: Store below 30°C, keep in the original blister pack.

• National Institutes of Health (NIH) – Ondansetron Drug Profile
• World Health Organization (WHO) – Guidelines for Antiemetic Use
• FDA Label Information for Ondansetron
• European Medicines Agency (EMA) Ondansetron Safety Guidelines